UroGen Pharma Earnings Preview

UroGen Pharma (NASDAQ:URGN) is set to give its latest quarterly earnings report on Monday, 2026-03-02. Here's what investors need to know before the announcement.

Analysts estimate that UroGen Pharma will report an earnings per share (EPS) of $-0.57.

Anticipation surrounds UroGen Pharma's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.

New investors should understand that while earnings performance is important, market reactions are often driven by guidance.

Past Earnings Performance

Last quarter the company beat EPS by $0.01, which was followed by a 1.27% drop in the share price the next day.

Here's a look at UroGen Pharma's past performance and the resulting price change:

Quarter	Q3 2025	Q2 2025	Q1 2025	Q4 2024
EPS Estimate	-0.70	-0.83	-0.80	-0.72
EPS Actual	-0.69	-1.05	-0.92	-0.80
Price Change %	-1.27	-4.55	-8.98	9.07

Performance of UroGen Pharma Shares

Shares of UroGen Pharma were trading at $21.18 as of February 26. Over the last 52-week period, shares are up 128.05%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release.

To track all earnings releases for UroGen Pharma visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.